ASST Papa Giovanni XXIII | Ospedale di Bergamo - SC Malattie Endocrine-Diabetologia

Research site

(Unclaimed)

Location

PIAZZA OMS 1, BERGAMO, Bergamo, Italy

Site insights

Top conditions

Top treatments

Atezolizumab

Nivolumab

Ruxolitinib

Gemcitabine

Cisplatin

Doxorubicin

Polatuzumab

Pembrolizumab

Trastuzumab

Odevixibat

Parent organization

This site is a part of ASST Papa Giovanni XXIII

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

42 of 127 total trials

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling

Heart Failure

Drug: Placebo

Drug: Ziltivekimab

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician...

Enrolling

Metastatic HER2-positive Breast Cancer

Drug: Trastuzumab

Drug: Gemcitabine

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)

This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R M...

Active, not recruiting

Multiple Myeloma

Drug: Cevostamab

Drug: Tocilizumab

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (Krascendo 1)

The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib...

Enrolling

KRAS G12C Lung Cancer

Non-Small Cell Lung Cancer

Drug: Sotorasib

Drug: Divarasib

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (CAMMA 1)

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab m...

Active, not recruiting

Multiple Myeloma

Drug: Daratumumab

Drug: Tocilizumab

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) (CADENCE)

This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults wit...

Active, not recruiting

Hypertension, Pulmonary

Drug: Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg

Drug: Placebo

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling

Biochemically Recurrent Prostate Cancer

Other: Placebo matching darolutamide

Drug: Darolutamide (BAY1841788, Nubeqa)

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve U...

Enrolling

Melanoma

Drug: ABP 206

Drug: Nivolumab

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPD...

Active, not recruiting

Melanoma

Drug: EU-authorized Nivolumab

Drug: ABP 206

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) (IMCODE004)

The main purpose of the study is to evaluate the efficacy of adjuvant treatment with autogene cevumeran plus nivolumab compared with nivolumab in par...

Enrolling

Muscle Invasive Urothelial Carcinoma

Drug: Autogene Cevumeran

Drug: Nivolumab

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immuno...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Docetaxel

Drug: Entrectinib

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling

Idiopathic Pulmonary Fibrosis

Drug: BMS-986278

Drug: BMS-986278 Placebo

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling

Progressive Pulmonary Fibrosis

Drug: BMS-986278 Placebo

Drug: BMS-986278

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients with Prostate Cancer (OncoACP-3)

The aim of this study is to assess the safety and dosimetry of \[68Ga\]Ga-OncoACP3 in patients with prostate cancer.

Not yet enrolling

PSA Level Greater Than 0.2

Prostate Cancer Metastatic Disease

Drug: [68Ga]Ga-OncoACP3

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients with CAIX-positive Cancer

Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.

Not yet enrolling

Clear Cell Renal Cell Carcinoma (ccRCC)

Drug: [68Ga]Ga-OncoCAIX

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) i...

Enrolling

Lymphoma, Non-Hodgkin

Drug: Glofitamab

Drug: Obinutuzumab

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC...

Active, not recruiting

Melanoma

Drug: nivolumab+rHuPH20

Drug: relatlimab+nivolumab

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Active, not recruiting

High-risk Transient Ischemic Attack

Acute Non-cardioembolic Ischemic Stroke

Drug: Asundexian (BAY2433334)

Drug: Placebo

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People ca...

Begins enrollment in 1 month

Heart Failure

Drug: Placebo matching vicadrostat

Drug: Empagliflozin

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling

Heart Failure

Drug: vicadrostat

Drug: Empagliflozin